Skip to main content

5 Result(s)

within Tomoko Asano Remove this filter Surgical Oncology Remove this filter

and

  1. No Access

    Article

    Predictive factors for patients who need treatment for chronic post-surgical pain (CPSP) after breast cancer surgery

    Although chronic postsurgical pain (CPSP) after breast cancer surgery is a common and prevalent postsurgical adverse event, the need for CPSP treatment has not been investigated. This study examined the propor...

    Yasuaki Uemoto, Megumi Uchida, Naoto Kondo, Yumi Wanifuchi-Endo… in Breast Cancer (2021)

  2. No Access

    Article

    HER2 mutation status in Japanese HER2-positive breast cancer patients

    Human epidermal growth factor receptor 2 (HER2) gene amplification/overexpression is a major therapeutic target in breast cancer, and has been introduced as a predictive biomarker to identify patients who may be...

    Yumi Endo, Yu Dong, Naoto Kondo, Nobuyasu Yoshimoto, Tomoko Asano… in Breast Cancer (2016)

  3. No Access

    Article

    Prognostic impact of a single-nucleotide polymorphism near the CTSO gene in hormone receptor-positive breast cancer patients

    Tamoxifen can reduce the occurrence of breast cancer by a half in high-risk women. Recently, a genome-wide association study identified two single-nucleotide polymorphisms (SNPs) near or in the CTSO and ZNF423 ge...

    Yukari Hato, Naoto Kondo, Nobuyasu Yoshimoto… in International Journal of Clinical Oncology (2016)

  4. No Access

    Article

    FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer

    Recent studies have indicated that the response to chemotherapy and the prognostic impact of a pathological complete response (pCR) after neoadjuvant chemotherapy differ among breast cancer subtypes. Predictor...

    Mai Kawase, Tatsuya Toyama, Satoru Takahashi, Shinya Sato… in Breast Cancer (2015)

  5. Article

    Open Access

    Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer

    There are many molecular differences between estrogen receptor α (ERα)-positive and ER-negative breast cancers. Recent analyses have shown that the former can be divided into two subtypes, luminal A and lumina...

    Yumi Endo, Hiroko Yamashita, Satoru Takahashi, Shinya Sato… in BMC Cancer (2014)

    Download PDF (597 KB) View Article